Latest Industry Updates
From company milestones to industry breakthroughs, uncover the stories making waves and shaping the narrative in real time.
- Press Release
King of Prussia, PA – October 12, 2023: CluePoints, the premier provider of Risk-Based Study Execution...
- Featured Article
At the recent DIA 2023 Global Annual Conference, I focused my attention on discussions about the...
Source: Clinical Research News
- Featured Article
CluePoints Co-Founder and Chief Product & Technology Officer François Torche discusses the challenges of collecting clinical...
Source: DIA
- Featured Article
A conversation with Steve Young, member of Avoca Quality Consortium, PHUSE Working Group participant, and Tufts...
Source: Clinical Leader
- Featured Article
The pharmaceutical industry has a problem – a failure to provide women with C-suite opportunities.
...Source: International Clinical Trials
- Press Release
King of Prussia, PA – August 9, 2023: CluePoints, the premier provider of Risk-Based Study Execution...
- Featured Article
The ICH E6(R3) draft guideline document, currently open to public consultation, places the industry firmly in...
Source: Applied Clinical Trials
- Press Release
King of Prussia, PA – August 1, 2023: CluePoints, the premier provider of Risk-Based Quality Management...
- Featured Article
Despite the push for greater use of risk-based quality management (RBQM) in clinical research, adoption of...
Source: CenterWatch
- Featured Article
Central monitoring aims to detect emerging quality-related risks proactively during a clinical trial, resulting in study...
Source: Applied Clinical Trials
- Press Release
King of Prussia, PA – June 20, 2023: CluePoints, the premier provider of Risk-Based Study Execution...
- Press Release
King of Prussia, PA – May 3, 2023: CluePoints, the premier provider of Risk-Based Study Execution...
- Press Release
On July 28, CluePoints is teaming up with DIA for a webinar to explore how the...
- Press Release
Personalizing the Power of Statistical Analysis and Data Visualization King of Prussia, PA: CluePoints, the premier...
- Press Release
RISK MANAGEMENT SOLUTION ADDRESSES FDA, EMA, PMDA & MHRA CORONAVIRUS ADVICE King of Prussia, PA: CluePoints,...
- Press Release
King of Prussia, PA: CluePoints, the premier provider of Risk-Based Study Execution (RBx) and Data Quality...
- Press Release
Risk Planning Guidance Addresses FDA, EMA, PMDA and MHRA Coronavirus Advice King of Prussia, PA: CluePoints,...
- Press Release
We’re delighted to announce that the recording for our COVID-19 webinar has been posted! About the...
- Press Release
Remote monitoring is mitigating the impact of SARS-CoV-2 on clinical trials, marking an acceleration in the...
- Press Release
King of Prussia, PA: CluePoints, the premier provider of Risk-Based Study Execution (RBx) and Risk-Based Quality...
- Press Release
KING OF PRUSSIA, PA: CluePoints, the premier provider of Risk-Based Study Execution (RBx) and Data Quality...
- Press Release
KING OF PRUSSIA, PA– FDA and its stakeholders have an interest in assuring the integrity of...
- Press Release
“I KNOW ICH E6 (R2) COMPLIANCE INSISTS ON A RISK-BASED APPROACH TO RUNNING MY TRIALS, BUT...
- Press Release
Strategic collaboration leverages CluePoints’ Central Statistical Monitoring (CSM) technology to enhance data quality and reduce operational...
- Featured Article
The pharmaceutical industry has a problem – a failure to provide women with C-suite opportunities.
...Source: International Clinical Trials
- Featured Article
The ICH E6(R3) draft guideline document, currently open to public consultation, places the industry firmly in...
Source: Applied Clinical Trials
- Featured Article
Despite the push for greater use of risk-based quality management (RBQM) in clinical research, adoption of...
Source: CenterWatch
- Featured Article
Central monitoring aims to detect emerging quality-related risks proactively during a clinical trial, resulting in study...
Source: Applied Clinical Trials
- Featured Article
Using key risk indicators (KRIs) can improve clinical trial data quality in 80% of the sites...
Source: Applied Clinical Trials
- Featured Article
Since the release of ICH E6(R2), multiple efforts have been made to interpret the requirements and...
- Read
Source: Springer Link
- Featured Article
An expectation for the use of quality tolerance limits (QTLs) was formally established in the International...
Source: Applied Clinical Trials
- Featured Article
Clinical research is evolving rapidly, with the digitalization of trials creating a new modus operandi and...
Source: Applied Clinical Trials
- Featured Article
Risk-based approaches to monitoring clinical trials were brought to the forefront with an FDA guidance published...
Source: Applied Clinical Trials
- Featured Article
Key risk indicators (KRIs) are metrics designed to identify risks of specific interest to study teams...
Source: Applied Clinical Trials
- Featured Article
The success of clinical development programmes, drug approval and marketing depends ultimately on the readability and...
Source: International Clinical Trials
- Featured Article
Central monitoring, which typically includes the use of key risk indicators (KRIs), aims at improving the...
Source: Springer Link